Venous Thromboembolic Disease
Conditions
Keywords
Venous, Thromboembolic, Direct Oral Anticoagulants, AOD, Cost analysis, REMOTEV, AVK, Pulmonary embolism
Brief summary
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first intention.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major patient whose age is ≥18 years * Patient with a diagnosis of MTEV: pulmonary embolism or deep vein thrombosis diagnosed by the diagnostic reference methods according to the recommendations * Major patient included in the REMOTEV registry * Patient having accepted that his data recorded in the REMOTEV register be re-used for research and publication purposes Criteria of non-inclusion * Refusal to participate in the REMOTEV register * Patient who refused to have his data reused for research and publication purposes * Pregnant woman * Subjects under safeguard of justice Subject under guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cost-effectiveness analysis between 2 therapeutic strategies, Direct Oral Anticoagulants (Rivaroxaban) versus standard anticoagulant (AVK) | The period from November 1st, 2013 to July 01, 2015 will be examined | Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs. |
Countries
France
Contacts
Primary ContactDominique STEPHAN, MD, PhD
Backup ContactElena-Mihaela CORDEANU, MD
Outcome results
None listed